Statement about Media Articles as to Takeda's Acquisition of a Swiss Company

Osaka, Japan, May 13, 2011 --- Takeda Pharmaceutical Company Limited ("Takeda") has and always will comply with the rules governing the publication of any event of material significance to our business and our shareholders. The company would like to make clear that Takeda has not agreed to any such an agreement as suggested by certain newspaper publications. In addition, Takeda has a policy of not commenting on any rumors regarding our business.

Takeda is constantly seeking and evaluating opportunities to increase shareholder value and enhance our business through strategic investment, however, there is nothing that needs to be announced at this point.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.